Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
461-480 of 936 trials

HER2-Positive Glioblastoma: NK-92/5.28.z Cells and Ezabenlimab

We are investigating a new treatment combining NK-92/5.28.z cells with Ezabenlimab for patients with recurrent HER2-positive glioblastoma. This study aims to see if this combination can improve treatment outcomes.

Glioblastoma>2 yearsSafety phase (I)NeurologyOncology

Colorectal Cancer: STC-1010 Immunotherapy

We are studying a new immunotherapy for patients with advanced colorectal cancer that cannot be surgically removed. The trial aims to evaluate its safety and effectiveness alongside standard treatment options.

Unresectable Locally Advanced or Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Genetically Modified T-Cells for ROR1 Positive Tumors

We are assessing the safety and tolerability of a new treatment using genetically modified T-cells for patients with ROR1 positive tumors. This study aims to understand how these cells may help in treating this type of cancer.

Mantle Cell LymphomaOvarian CancerAdrenocortical Carcinoma>2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: DS-2243a Treatment

We are testing a new drug called DS-2243a in people with advanced solid tumors. This study aims to see how safe it is and how well it works compared to existing treatments.

Advanced Solid Tumor>2 yearsSafety phase (I)Oncology

B-cell Non-Hodgkin Lymphoma: Loncastuximab Tesirine Study

We are testing a new treatment combining Loncastuximab Tesirine with other anti-cancer agents for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma. The goal is to evaluate its safety and potential effectiveness.

B-cell Non-Hodgkin's Lymphoma>2 yearsSafety phase (I)Oncology

CNS Lymphoma: [90Y]Y-PentixaTher Therapy

We are studying the safety and effectiveness of [90Y]Y-PentixaTher in patients with recurrent or refractory central nervous system lymphoma. This trial aims to find the best dose and understand how the treatment works in the body.

CNS LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Multiple Myeloma: Etentamig and Iberdomide Study

We are investigating the safety and effects of a new treatment combining etentamig and iberdomide for patients with relapsed or refractory multiple myeloma. This study aims to find the best doses and assess how well the treatment works.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Breast Cancer: New Eye Safety Drug Study

We are investigating the safety of a new drug for breast cancer patients, specifically looking at its effects on eye health. This study aims to ensure that the treatment does not harm vision.

Breast Cancer>2 yearsSafety phase (I)OncologyOphthalmology

Solid Cancers: NILK-2401 Antibody Study

We are testing a new antibody treatment for solid cancers, both alone and with another cancer therapy. This study aims to find out how effective it may be for patients.

Advanced Solid Tumor>2 yearsSafety phase (I)Oncology

Non-Ischemic Dilated Cardiomyopathy: SECRET-HF Treatment

We are exploring whether infusions of a cell-derived product can improve heart function in patients with non-ischemic dilated cardiomyopathy. This study aims to find new treatment options for this condition.

Non-ischemic Dilated Cardiomyopathy>2 yearsSafety phase (I)Cardiology

Advanced Solid Tumors: ORIC-114 Study

We are testing a new drug, ORIC-114, for patients with advanced solid tumors that have EGFR or HER2 alterations. The study will assess its safety and effectiveness alone and with chemotherapy.

Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Advanced Colorectal Cancer: pTTL Immunotherapy

We are testing a new T cell immunotherapy called pTTL for patients with advanced colorectal cancer. This study aims to see how well it works and its safety in humans.

Colorectal Cancer>2 yearsSafety phase (I)Oncology

Colorectal Cancer: FAPI-PET Imaging Study

We are investigating whether FAPI-PET imaging can help detect tumor-associated fibrosis in patients with colorectal peritoneal metastases. This may improve diagnosis and treatment planning.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)GastroenterologyOncology

LPH-5: First-in-Man Safety Study

We are investigating a new drug called LPH-5 in healthy volunteers to see how safe it is and how it works in the body. This study will help us understand its effects compared to a placebo.

Depression6-12 monthsSafety phase (I)Psychiatry

Prostate Cancer: New Radioactive Treatment Study

We are testing a new radioactive drug for adults with metastatic castration-resistant prostate cancer who have not had chemotherapy. The study will assess the safety and how well the treatment works in these patients.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Standard MedicinesOncology

RCS-21: Safety Study in Healthy Volunteers

We are testing the safety and tolerability of the compound RCS-21 in healthy individuals. This study will help us understand how the body absorbs and eliminates this drug.

Healthy Participants1-2 yearsSafety phase (I)Pulmonology

Solid Tumors: MCLA-128 Treatment Study

We are studying a new bispecific antibody, MCLA-128, in patients with solid tumors that have an NRG1 fusion. The goal is to evaluate its safety and how well it may work against these tumors.

Solid TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Solid Tumors: STP938 Treatment Study

We are testing a new drug called STP938 in adults with advanced solid tumors, including those with a specific type of ovarian cancer. The study aims to evaluate the safety of this treatment.

Ovarian CancerSolid Tumors>2 yearsSafety phase (I)Oncology

PRT7732 for Advanced Solid Tumors with SMARCA4 Mutation

We are testing a new oral medication for patients with advanced or metastatic solid tumors that have a specific genetic mutation. The goal is to see if it can help improve treatment outcomes.

Esophageal, Gastric, or Gastroesophageal Junction AdenocarcinomaEsophageal, Gastric, or Gastroesophageal Junction Squamous Cell CarcinomaNon-Small Cell Lung Cancer (NSCLC)>2 yearsSafety phase (I)Oncology

Tumor Treatment: ABX-001 Immunotherapy

We are testing a new immunotherapy, ABX-001, alone and with pembrolizumab for patients with tumors that have been treated before. The goal is to see if this combination can improve treatment outcomes.

Advanced Solid Tumors1-2 yearsSafety phase (I)Oncology